Laurion Capital Management’s Royalty Pharma RPRX Stock Holding History

Laurion Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21,347	Closed	-$832K	–	665
2022 Q1	$832K	Hold	21,347	–	–	0.01%	263
2021 Q4	$851K	Hold	21,347	–	–	0.01%	357
2021 Q3	$771K	Hold	21,347	–	–	﹤0.01%	532
2021 Q2	$875K	Sell	21,347 -28,653	-57%	-$1.22M	﹤0.01%	457
2021 Q1	$2.18M	Sell	50,000 -8,000	-14%	-$379K	0.01%	419
2020 Q4	$2.9M	Buy	58,000 +8,000	+16%	+$339K	0.02%	307
2020 Q3	$2.1M	Hold	50,000	–	–	0.03%	304
2020 Q2	$2.43M	Buy	+50,000	New	+$2.47M	0.03%	307

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Laurion Capital Management's RPRX Position: Q2 2022 in Review

Laurion Capital Management sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 21,347 shares — an estimated $832K sold.

Laurion Capital Management first reported a position in RPRX in Q2 2020 and held it in 8 quarters. The position peaked at $2.9M in Q4 2020. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

Laurion Capital Management reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
Laurion Capital Management sold 21,347 Royalty Pharma shares in Q2 2022, an estimated $832K.
Laurion Capital Management first reported a position in Royalty Pharma in Q2 2020 and held it in 8 quarters.
Laurion Capital Management's Royalty Pharma position peaked at $2.9M in Q4 2020.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.